Buprenorphine/naloxone - Indivior

Drug Profile

Buprenorphine/naloxone - Indivior

Alternative Names: Buprenorphine hemiadipate HCl/naloxone HCl dihydrate; Buprenorphine hemiadipate hydrochloride/naloxone hydrochloride dihydrate; RBP-6300

Latest Information Update: 08 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Reckitt Benckiser Pharmaceuticals
  • Developer Indivior
  • Class Antidotes; Cyclopropanes; Drug withdrawal therapies; Morphinans; Opioid analgesics; Small molecules
  • Mechanism of Action Nociceptin receptor agonists; Opioid delta receptor antagonists; Opioid kappa receptor antagonists; Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Opioid abuse

Most Recent Events

  • 03 May 2016 Discontinued - Phase-I for Opioid abuse in United Kingdom (PO)
  • 03 May 2016 Discontinued - Phase-II for Opioid abuse (In volunteers) in United Kingdom (PO)
  • 03 May 2016 Discontinued - Phase-II for Opioid abuse in Sweden, Germany, Czech Republic, Austria (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top